312-422-1111 ibioadmin@ibio.org
BioVie Receives $3.2 Million Equity Investment

BioVie Receives $3.2 Million Equity Investment

On July 3, 2018, BioVie Inc. (OTCQB: BIVI), an iBIO PROPEL company developing innovative drug therapies for liver disease, executed an agreement with Acuitas Group Holdings, LLC (“Acuitas”) and certain other investors to purchase $3.2 million of the Company’s Series A...
X